These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
198 related articles for article (PubMed ID: 11336614)
1. Review of rivastigmine and its clinical applications in Alzheimer's disease and related disorders. Desai A; Grossberg G Expert Opin Pharmacother; 2001 Apr; 2(4):653-66. PubMed ID: 11336614 [TBL] [Abstract][Full Text] [Related]
2. Rivastigmine. A review of its use in Alzheimer's disease. Spencer CM; Noble S Drugs Aging; 1998 Nov; 13(5):391-411. PubMed ID: 9829166 [TBL] [Abstract][Full Text] [Related]
3. Rivastigmine, a new-generation cholinesterase inhibitor for the treatment of Alzheimer's disease. Jann MW Pharmacotherapy; 2000 Jan; 20(1):1-12. PubMed ID: 10641971 [TBL] [Abstract][Full Text] [Related]
4. A phase II study in patients with Alzheimer's disease to assess the preliminary efficacy and maximum tolerated dose of rivastigmine (Exelon). Forette F; Anand R; Gharabawi G Eur J Neurol; 1999 Jul; 6(4):423-9. PubMed ID: 10362894 [TBL] [Abstract][Full Text] [Related]
5. Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial. Farlow M; Potkin S; Koumaras B; Veach J; Mirski D Arch Neurol; 2003 Jun; 60(6):843-8. PubMed ID: 12810489 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of rivastigmine in patients with Alzheimer's disease who failed to benefit from treatment with donepezil. Auriacombe S; Pere JJ; Loria-Kanza Y; Vellas B Curr Med Res Opin; 2002; 18(3):129-38. PubMed ID: 12094822 [TBL] [Abstract][Full Text] [Related]
10. Effects of rivastigmine on behavioral and psychological symptoms of dementia in Alzheimer's disease. Finkel SI Clin Ther; 2004 Jul; 26(7):980-90. PubMed ID: 15336465 [TBL] [Abstract][Full Text] [Related]
11. Rivastigmine for Alzheimer's disease. Drug Ther Bull; 2000 Feb; 38(2):15-6. PubMed ID: 10829350 [TBL] [Abstract][Full Text] [Related]
12. Savings in the cost of caring for patients with Alzheimer's disease in Canada: an analysis of treatment with rivastigmine. Hauber AB; Gnanasakthy A; Mauskopf JA Clin Ther; 2000 Apr; 22(4):439-51. PubMed ID: 10823365 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. Rösler M; Anand R; Cicin-Sain A; Gauthier S; Agid Y; Dal-Bianco P; Stähelin HB; Hartman R; Gharabawi M BMJ; 1999 Mar; 318(7184):633-8. PubMed ID: 10066203 [TBL] [Abstract][Full Text] [Related]
15. Preserved cognitive function after 12 months of treatment with rivastigmine in mild Alzheimer's disease in comparison with untreated AD and MCI patients. Almkvist O; Darreh-Shori T; Stefanova E; Spiegel R; Nordberg A Eur J Neurol; 2004 Apr; 11(4):253-61. PubMed ID: 15061827 [TBL] [Abstract][Full Text] [Related]
16. Understanding and managing behavioural symptoms in Alzheimer's disease and related dementias: focus on rivastigmine. Robert P Curr Med Res Opin; 2002; 18(3):156-71. PubMed ID: 12094826 [TBL] [Abstract][Full Text] [Related]
17. The clinical benefits of rivastigmine may reflect its dual inhibitory mode of action: an hypothesis. Bullock R Int J Clin Pract; 2002 Apr; 56(3):206-14. PubMed ID: 12018828 [TBL] [Abstract][Full Text] [Related]
18. Potential long-term effects of rivastigmine on disease progression may be linked to drug effects on vascular changes in Alzheimer brains. Erkinjuntti T; Skoog I; Lane R; Andrews C Int J Clin Pract; 2003 Nov; 57(9):756-60. PubMed ID: 14686563 [TBL] [Abstract][Full Text] [Related]